{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:41:58Z","timestamp":1774262518093,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":3485,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1016\/s1535-6108(04)00002-9","type":"journal-article","created":{"date-parts":[[2004,3,30]],"date-time":"2004-03-30T10:20:32Z","timestamp":1080642032000},"page":"19-24","source":"Crossref","is-referenced-by-count":230,"title":["Focus on epithelial ovarian cancer"],"prefix":"10.1016","volume":"5","author":[{"given":"Robert F.","family":"Ozols","sequence":"first","affiliation":[]},{"given":"Michael A.","family":"Bookman","sequence":"additional","affiliation":[]},{"given":"Denise C.","family":"Connolly","sequence":"additional","affiliation":[]},{"given":"Mary B.","family":"Daly","sequence":"additional","affiliation":[]},{"given":"Andrew K.","family":"Godwin","sequence":"additional","affiliation":[]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[]},{"given":"Xiangxi","family":"Xu","sequence":"additional","affiliation":[]},{"given":"Thomas C.","family":"Hamilton","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1535-6108(04)00002-9_BIB1","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1073\/pnas.92.12.5258","article-title":"The causes and prevention of cancer","volume":"92","author":"Ames","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3322\/canjclin.52.4.216","article-title":"Paradigms for primary prevention of ovarian carcinoma","volume":"52","author":"Barnes","year":"2002","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.7-suppl_4-2","article-title":"Why the epidermal growth factor receptor? The retionale for cancer therapy","volume":"7","author":"Baselga","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB4","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/JCO.2003.02.553","article-title":"Developmental chemotherapy and management of recurrent ovarian cancer","volume":"21","author":"Bookman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1006\/gyno.2000.6065","article-title":"Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer","volume":"80","author":"Brown","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB7","first-page":"717","article-title":"Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis","volume":"71","author":"Cramer","year":"1983","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1097-2765(03)00424-6","article-title":"Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair","volume":"12","author":"Dong","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1095\/biolreprod50.2.233","article-title":"Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction","volume":"50","author":"Espey","year":"1994","journal-title":"Biol. Reprod."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation\u2014a factor in ovarian neoplasia?","volume":"17","author":"Fathalla","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2559.2001.01042.x","article-title":"Precursor lesions of ovarian epithelial malingnancy","volume":"38","author":"Feeley","year":"2001","journal-title":"Histopathology"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB12","first-page":"208a","article-title":"Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma","volume":"20","author":"Finkler","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0092-8674(02)01052-8","article-title":"BRCA1 supports XIST RNA concentration on the inactive X chromosome","volume":"111","author":"Ganesan","year":"2002","journal-title":"Cell"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jnci\/84.8.592","article-title":"Spontaneous transformation of rat ovarian surface epithelial cells","volume":"84","author":"Godwin","year":"1992","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.1073834","article-title":"Biallelic inactivation of BRCA2 in Fanconi anemia","volume":"297","author":"Howlett","year":"2002","journal-title":"Science"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB16","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0002-9440(10)64467-7","article-title":"Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer","volume":"161","author":"Hu","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","article-title":"Cancer statistics, 2003","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB18","doi-asserted-by":"crossref","unstructured":"King, M., Marks, J.H., and Mandell, J.B., for the New York Breast Cancer Study Group. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643\u2013646.","DOI":"10.1126\/science.1088759"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.288.3.334","article-title":"Menopausal hormone replacement therapy and risk of ovarian cancer","volume":"288","author":"Lacey","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer","volume":"18","author":"Muggia","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001703-200202000-00004","article-title":"Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer","volume":"14","author":"Narod","year":"2002","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/jnci\/91.17.1459","article-title":"Possible role of ovarian epithelial inflammation in ovarian cancer","volume":"91","author":"Ness","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/92.2.163","article-title":"Response to","volume":"92","author":"Ness","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB25","article-title":"Pathology of ovarian neoplasms in genetically modified mice","volume":"in press","author":"Nikitin","year":"2004","journal-title":"Comp. Med."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB26","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of proteomic patterns in serum to identify ovarian cancer","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB28","series-title":"American Cancer Society Atlas of Clinical Oncology","first-page":"49","article-title":"The genetics of ovarian cancer","author":"Prowse","year":"2003"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB29","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2265.1998.00577.x","article-title":"Hormonal aspects of epithelial ovarian cancer","volume":"49","author":"Riman","year":"1998","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB31","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.11847","article-title":"Loss of surface and cyst epithelial basement membranes and pre-neoplastic morphological changes in prophylactic oophorectomies","volume":"98","author":"Roland","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB32","first-page":"2923","article-title":"Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer","volume":"62","author":"Sawiris","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB33","first-page":"451","article-title":"Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer","volume":"22","author":"Schilder","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB34","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1002\/cncr.11848","article-title":"Prophylactic oophorectomy","volume":"98","author":"Schlosshauer","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB35","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nm852","article-title":"Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors","volume":"9","author":"Taniguchi","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB36","first-page":"2778","article-title":"Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity","volume":"54","author":"Testa","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.105","article-title":"International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial","volume":"95","author":"Trimbos","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1535-6108(04)00002-9_BIB38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"(The International Collaborative Ovarian Neoplasm Group)Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer","volume":"360","author":"ICON","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1634\/theoncologist.5-suppl_1-45","article-title":"Targeting vascular endothelial growth factor blockade","volume":"5","author":"Verheul","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/S1535-6108(04)00002-9_BIB40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(03)01139-2","article-title":"Why did p53 gene therapy fail in ovarian cancer?","volume":"4","author":"Zeimet","year":"2003","journal-title":"Lancet Oncol."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610804000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610804000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T10:27:08Z","timestamp":1550140028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610804000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S1535610804000029"],"URL":"https:\/\/doi.org\/10.1016\/s1535-6108(04)00002-9","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}